REV-ERB agonist is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-11-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | SR9009; Stenabolic | Nickname is not a chemical name. |
| Typical analytical method | LC-MS/MS | Often with isotope-labeled internal standard. |
| Storage temperature | -20 °C | Desiccated and protected from light. |
| Solution stability | DMSO stock; avoid freeze-thaw | Store at -20 to -80 °C. |
| Regulatory status | Not approved; varies by country | May be restricted as research chemical. |
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
proteinase Also endopeptidase or endoproteinase. Any enzyme that catalyzes the hydrolysis of peptide bonds more readily in intact, properly folded proteins than in small peptide molecules. Proteinases may be considered a subclass of proteases, though the terms are also often used interchangeably.
== Toxicity == The toxicity of organomercury compounds presents both dangers and benefits. Dimethylmercury in particular is notoriously toxic, but found use as an antifungal agent and insecticide. Merbromin and phenylmercuric borate are used as topical antiseptics, while thimerosal is safely used as a preservative for vaccines and antitoxins.
=== Notable applications === With the development of native chemical ligation in 1994, total chemical synthesis of pairs of D-protein and L-protein enantiomers became feasible. In the first practical application to solving an unknown structure, racemic and quasi-racemic X-ray crystallography were used to determine the structure of snow flea anti-freeze protein. In the course of that work it was observed that racemic and even quasi-racemic protein mixtures dramatically facilitated the formation of diffraction quality, centrosymmetric crystals. Quasi-racemates are formed by mirror image protein molecules that are not true enantiomers but which are sufficiently similar mirror image objects to form ordered pseudo-centrosymmetric arrays. Subsequently, pairs of racemic and quasi-racemic protein molecules prepared by total chemical synthesis have been shown to dramatically increase the rate of success in forming diffraction-quality crystals from a wide range of globular protein molecules. Rv1738, a protein of Mycobacterium tuberculosis is the most up-regulated gene product when M. tb enters persistent dormancy. Preparations of recombinantly expressed Rv1738 L-protein resisted extensive attempts to form crystals. A racemic mixture of the chemically synthesized D-protein and L-protein forms of Rv1738 gave crystals in the centrosymmetric space group C2/c. The structure, containing L-protein and D-protein dimers in a centrosymmetric space group, revealed structural similarity to 'hibernation-promoting factors' that can bind to ribosomes and suppress translation.
In the latter, births were limited as they had no more places in the ICU/neonatal unit. Some pregnant women in the hospitals had COVID-19, with some of them going into intensive care. Some had premature births, with them being directly sent to the ICU. Even ahead of the overcrowding of ICUs and the collapse of the health system, Melo, on 16 March, decreed his opposition to the construction of field hospitals and that it is always the case that more people could be admitted to already existing hospitals. On 21 March, the state government published a decree to authorize the retaking of co-management. Up to that point, Porto Alegre had suffered from an overcapacity of hospital beds for three weeks. Melo immediately adopted red flag measures, including the reopening of businesses, bars and restaurants, even with the health system collapsing. Days after, he admitted to not having any scientific basis for his decision. In a public declaration, Melo said that he would not spend not even a cent in hiring new inspectors to implement the laws and confirm if the sanitary protocols have been complied with. Along with this, he reiterated that he would not implement the state decree that required the usage of masks. On 26 March, even with hospitals dealing with overcapacity, Melo published a decree allowing for the opening of bars, restaurants, and businesses with hours that were not permitted by the state government.
Sources: en.wikipedia.org
=== History of thalassemia === Rudolf Von Jaksch in 1889 first described "anaemia leucaemic infantum" as a form of chronic anemia in children which combined with an enlarged spleen, and abnormal size and shape of the red blood cells. His discovery was subsequently found to comprise a collection of different conditions. The first definitive identification of a thalassemia was in 1925 by Thomas Benton Cooley, an American pediatrician specialising in hematology and childhood anemias. Cooley noted similarities in symptoms of children in his care having Greek or Italian ancestry; he named it "erythroblastic anemia," but it became popularly known as Cooley's anemia (now termed beta thalassemia major). The term "thalassemia" was coined by George Whipple in 1932. The word "thalassemia" comes from the Greek word thalassa, which means "sea". The suffix "-emia" comes from the Greek word haima, which means "blood". The term was coined because the condition was strongly associated with people of Mediterranean descent. In 1948, Italian researchers established that the type of thalassemia which was prevalent in Italy was inherited in a recessive pattern.
=== History === Obtaining a medical history is always the first "test", part of understanding the likelihood of significant disease, as detectable within the current limitations of clinical medicine. Yet heart problems often produce no symptoms until very advanced, and many symptoms, such as palpitations and sensations of extra or missing heart beats correlate poorly with relative heart health vs disease. Hence, a history alone is rarely sufficient to diagnose a heart condition.
Bhagat Singh Thind stands as a significant milestone in U.S. legal history, shedding light on the intricate intersections of immigration, citizenship, and racial identity. It serves as a poignant reminder of the biases entrenched within immigration laws and the complexities of racial classifications in American society.
Studies have also been conducted on the effect of arsenic trioxide on other cancers. These showed that the drug also induces apoptosis in lung cancer cells (especially in combination with sulindac). The efficacy of arsenic trioxide has also been demonstrated in the treatment of multiple myeloma, in combination with ascorbic acid and bortezomib. Animal studies have shown that the drug also affects ovarian, liver, stomach, prostate, and breast cancers, as well as gliomas and pancreatic cancer (in combination with parthenolide). However, attempts to use arsenic trioxide in the treatment of solid tumors have been limited by the drug's toxicity. Arsenic trioxide also appears promising for treating autoimmune diseases (based on studies in mice).
=== Phase 2 === AGX-201 (histamine dihydrochloride salt) – histamine H1 receptor antagonist and histamine H3 receptor agonist – migraine [7] BHV-2100 – transient receptor potential cation channel subfamily M member 3 (TRPM3) antagonist – migraine [8] Botulinum toxin A longer acting (IPN-10200; mrBoNT) – acetylcholine release inhibitor and neuromuscular blocking agent – migraine [9] CAM-01 (C-AM-01) – undefined mechanism of action – migraine [10] Dihydroergotamine mesilate (DFN-19) – non-selective monoamine receptor modulator and ergoline – migraine [11] Doxepin intranasal (Dolorac) – tricyclic antidepressant (non-selective monoamine reuptake inhibitor and receptor modulator and other actions) – headache [12] Elismetrep (K-304; MT-8554) – transient receptor potential cation channel subfamily M member 8 (TRPM8) antagonist – migraine [13] Erenumab (Aimovig; AMG-334) – monoclonal antibody against calcitonin gene-related peptide receptor (CGRPR) – headache [14] Eslicarbazepine acetate (Aptiom; BIA 2-093; ESL; Exalief; SEP-0002093; SEP-2093; Stedesa; Zebinix) – sodium channel blocker – migraine [15] IONIS-PKKRx (ISIS-546254; ISIS-PKKRx) – antisense oligonucleotide against kallikrein – migraine [16] Ketoprofen topical (ELS-M11; Topofen) – COX inhibitor/NSAID – migraine [17] LAT-8881 (AOD9604; Tyr-hGH171191) – human growth hormone protein fragment and lanthionine synthetase C-like protein (LanCL) ligand – migraine [18] LU-AG09222 (ALD-1910) – monoclonal antibody against pituitary adenylate cyclase-activating polypeptide (PACAP) – migraine [19] LY-3451838 (PACAP-38 antibody) – monoclonal antibody against pituitary adenylate cyclase-activating polypeptide (PACAP) – migraine [20] Lysergic acid diethylamide (LSD; MM-120) – non-selective serotonin receptor agonist and psychedelic hallucinogen – cluster headache [21] MTX-101 – undefined mechanism of action – migraine [22] Pasireotide (Signifor; SOM-230) – somatostatin receptor agonist – cluster headache [23] Prabotulinumtoxin A (ABP-450; DWP-450; Evosyal; Jeuveau; Nabota; Nuceiva) – acetylcholine release inhibitor and neuromuscular blocking agent – migraine [24] Sepranolone (isoallopregnanolone; UC-1010) – GABAA receptor negative allosteric modulator and neurosteroid – menstrual migraine [25] TRV-250 – δ-opioid receptor (DOR) agonist – migraine [26] (R)-Verapamil – calcium channel blocker and other actions – cluster headache [27] Zelminemab (AMG-301) – monoclonal antibody against pituitary adenylate cyclase-activating polypeptide type I receptor (PAC1R) – migraine [28]
Sources: en.wikipedia.org
The main street in the city centre, Via Roma, runs atop a tunnel built during the fascist era (when Via Roma itself was totally refurbished and took on its present-day aspect). The tunnel was supposed to host the underground line, but it is now used as an underground car park. A project to build an underground system was ready in the 1970s, with government funding for it and for similar projects in Milan and Rome. Whilst the other two cities went ahead with the projects, Turin's local government led by mayor Diego Novelli shelved the proposal as it believed it to be too costly and unnecessary. The city has an international airport known as Caselle International Airport Sandro Pertini (airport code: TRN), in Caselle Torinese, about 13 km (8 mi) from Turin's centre—connected to the city by rail (from Dora Station) and bus (from Porta Nuova and Porta Susa railway stations). From 2010 to 2023 a bicycle sharing system, the ToBike, was operational. The metropolitan area is served by Turin metropolitan railway service. Central districts are served by tram; lines 3, 4, and 9 are light rail.
Several artificial nucleobases have been synthesized, and successfully incorporated in the eight-base DNA analogue named Hachimoji DNA. Dubbed S, B, P, and Z, these artificial bases are capable of bonding with each other in a predictable way (S–B and P–Z), maintain the double helix structure of DNA, and be transcribed to RNA. Their existence could be seen as an indication that there is nothing special about the four natural nucleobases that evolved on Earth. On the other hand, DNA is tightly related to RNA which does not only act as a transcript of DNA but also performs as molecular machines many tasks in cells. For this purpose it has to fold into a structure. It has been shown that to allow to create all possible structures at least four bases are required for the corresponding RNA, while a higher number is also possible but this would be against the natural principle of least effort.
All of these chemical identifiers, combined with distinct morphological features characteristic of tracheids allowed for the assignment of Protopodocarpoxylon to the sample. The presence of multiple biomarkers, each of which correspond to different groups of organisms allows potential identities to be narrowed down. When combined with phenotypic characteristics, specific biomarkers like sugiol become very strong tools in identifying unknown organisms.
Causes of T cell deficiency include lymphocytopenia of T cells and/or defects on function of individual T cells. Complete insufficiency of T cell function can result from hereditary conditions such as severe combined immunodeficiency (SCID), Omenn syndrome, and cartilage–hair hypoplasia. Causes of partial insufficiencies of T cell function include acquired immune deficiency syndrome (AIDS), and hereditary conditions such as DiGeorge syndrome (DGS), chromosomal breakage syndromes (CBSs), and B cell and T cell combined disorders such as ataxia-telangiectasia (AT) and Wiskott–Aldrich syndrome (WAS). The main pathogens of concern in T cell deficiencies are intracellular pathogens, including Herpes simplex virus, Mycobacterium and Listeria. Also, fungal infections are also more common and severe in T cell deficiencies.
=== America's "first opioid crisis" === The 1880s saw opiate addiction surge among housewives, doctors, and Civil War veterans, creating America's "first opioid crisis". By the end of the century, an estimated one in 200 Americans were addicted to opiates, 60% of them women, typically white and middle- to upper-class. Medical journals of the later 1800s were replete with warnings against overprescription. As medical advances presented better treatment options, prescribed opiate use began to decline. Meanwhile, opium smoking remained popular among Chinese immigrant laborers, thousands of whom had arrived during the California gold rush. The public face of opiate use began to change, from affluent white Americans, to "Chinese, gamblers, and prostitutes". During this period, states and municipalities began enacting laws banning or regulating certain drugs. In Pennsylvania, an anti-morphine law was passed in 1860. In 1875, San Francisco enacted an anti-opium ordinance, vigorously enforced, imposing stiff fines and jail for visiting opium dens. The rationale held that "many women and young girls, as well as young men of a respectable family, were being induced to visit the Chinese opium-smoking dens, where they were ruined morally and otherwise." The law catered to resentment towards the Chinese laborer population who were being accused of taking jobs; other uses of opiates or other drugs were unaffected. Similar laws were enacted in other states and cities. The federal government became involved, selectively raising the import tariff on the smoking grade of opium.
Sources: en.wikipedia.org
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.
Solid material is usually kept at -20 °C, desiccated, and protected from light. Dimethyl sulfoxide stocks should be stored cold and subjected to minimal freeze-thaw cycles. Aqueous solutions are generally less stable and should be prepared fresh when possible.
Legality depends on the country and the intended use. It is not an approved medicine, and some places restrict or ban sales for human consumption. Buyers should verify local rules and product documentation before procurement.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.